

Supplemental Table 2. Comparisons of clinical characteristics among co-infected, mono-infected and uninfected patients with tick-borne pathogens in northeastern China, 2010-2011.

Characteristics	Co-infected patients N=12 n (%)	Mono-infected patients N=63 n (%)	Uninfected patients N=105 n (%)	P_1	P_2
Male	5 (42)	41 (65)	56 (53)	0.2	0.5
Age, median (range), years	48 (27-66)	47 (7-73)	43 (1-80)	0.9	0.5
Interval from tick detection to illness onset, median (range), days	6 (0-25)	6 (0-33)	4 (0-55)	0.9	0.5
Any symptom	12 (100)	61 (97)	90 (86)	1.0	0.4
Numbers of symptom, median (range)	4 (1-8)	3 (0-8)	2 (0-8)	0.3	0.03
Erythema migrans	3 (25)	24 (39)	0	0.5	<0.001
Eschar	1 (8)	9 (14)	7 (7)	0.7	0.6
Multiple skin lesions	3 (25)	12 (19)	15 (14)	0.7	0.4
Lymphadenopathy	0	10 (16)	7 (7)	0.4	1
Fatigue	6 (50)	29 (46)	39 (37)	1	0.5
Headache	7 (58)	27 (43)	48 (46)	0.4	0.5
Dizziness	5 (42)	23 (37)	44 (42)	0.8	1
Myalgia	4 (33)	12 (19)	20 (19)	0.3	0.3
Fever	10 (83)	35 (56)	47 (45)	0.1	0.01
Neurological manifestation	2 (17)	16 (25)	8 (8)	0.8	0.3
Upper respiratory tract infection symptoms	0	3 (5)	9 (9)	1	0.6
Gastrointestinal symptoms	6 (50)	16 (25)	30 (29)	0.2	0.2
Arthralgia or swelling joint	3 (25)	7 (11)	11 (10)	0.2	0.2
Stiff neck	2 (17)	11 (17)	15 (14)	1	0.7

Inpatient	10 (83)	42 (67)	40 (38)	0.3	0.004
Hospitalization duration, median (range), days	23 (13-33)	19 (2-43)	18 (4-25)	0.1	0.02
Leukocyte count <4×10 ⁹ cells/L	1/11 (9)	11/58 (19)	7/83 (8)	0.7	1
Leukocyte count >10×10 ⁹ cells/L	5/11 (45)	14/58 (24)	16/83 (19)	0.3	0.07
Platelet count <100×10 ⁹ cells/L	1/11 (9)	1/58 (2)	6/83 (7)	0.3	1
Aspartate or alanine aminotransferase	2/7 (29)	15/31 (48)	12/29 (41)	0.3	0.7
Hemoglobin <120g/L	0/11 (0)	0/58 (0)	1/83 (1)	1	1
CSF cell count >8×10 ⁶ /L	7/8 (88)	8/16 (50)	3/7 (43)	0.2	0.1
CSF lymphocytic pleocytosis	7/8 (88)	6/16 (38)	2/7 (29)	0.03	0.04
CSF protein >0.45g/L	5/8 (63)	9/16 (56)	4/7 (57)	1	1

P₁: Comparison between co-infected and single infected patients; P₂: Comparison between co-infected and uninfected patients;